by GOAI

由GOAI生成

Share To

分享到

Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH (Metabolic Associated Steatohepatitis) pipeline. The agreement includes six preclinical siRNA (small interfering RNA) programs, which aim to address various aspects of liver disease and metabolic disorders.

Madrigal Pharmaceuticals 已達成一項獨家全球許可協議，以擴展其 MASH（代謝相關脂肪性肝炎）產品線。該協議包括六個臨牀前的 siRNA（小干擾 RNA）項目，旨在解決肝臟疾病和代謝紊亂的各個方面。

This development marks a significant addition to Madrigal’s research portfolio in the field of NASH (Nonalcoholic Steatohepatitis)..

這一進展標誌着Madrigal在NASH（非酒精性脂肪性肝炎）領域的研究組合中增加了重要的一部分。

The licensing deal grants Madrigal access to these six siRNA programs, which are currently in the preclinical stage. These programs focus on utilizing RNA interference technology to target specific pathways associated with liver diseases and metabolic dysfunctions. The company plans to integrate these programs into its existing pipeline for further development and potential clinical trials.

該許可協議授予麥德rigal公司訪問這六個siRNA項目，這些項目目前處於臨牀前階段。這些項目專注於利用RNA干擾技術靶向與肝臟疾病和代謝功能障礙相關的特定通路。該公司計劃將這些項目整合到其現有研發管線中，以進行進一步開發和潛在的臨牀試驗。

Details regarding the financial terms of the agreement or the timeline for advancing these programs have not been disclosed at this time..

目前尚未披露有關該協議的財務條款或推進這些計劃的時間表的細節。

Newsflash | Powered by GeneOnline AI

新聞快訊 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

來源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建議和反饋，請聯繫我們。

Date: The formatted date is: February 11, 2026

日期：格式化的日期為：2026年2月11日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 保留所有權利。與我們合作：

[email protected]

電子郵件地址

Author

作者

GOAI

GOAI

Related Post

相關文章